REG - SkinBioTherapeutics - Croda Commercial Launch Progressing as Expected

SkinbiotherapeuticsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd8625Oa&default-theme=true

RNS Number : 8625O  SkinBioTherapeutics PLC  30 June 2025

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Commercial Launch Progressing as Expected

 

30 June 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, reports that following the successful global launch of
Zenakine(TM) by Croda Beauty in April 2025, the commercialisation of the
product is progressing as expected by management.

 

According to the Croda Beauty website, Zenakine™ is being described as:

"…a cutting-edge neuroactive ingredient designed to counteract the effects
of stress on the skin and improve overall wellbeing. It works in sync with the
skin's natural biological rhythms, enhancing melatonin production to help
improve sleep quality, elevating positive emotions and stimulating skin
regeneration. It is the first ingredient with clinical instrumental measures
on sleep quality and duration benefits."

 

SkinBioTherapeutics has had a long standing commercial and manufacturing
agreement with Croda plc since 2019. As a result of the competitiveness of
the global cosmetic industry, SkinBioTherapeutics is under a strict
confidentiality agreement that prevents it from divulging information on sales
or providing market forecasts.

 

In the meantime, management will be holding a presentation for investors about
the recently signed commercial agreement with Superdrug on Thursday 3 July
2025 at 11am BST. For more information, please visit the Investor Meet Company
link HERE
(https://www.investormeetcompany.com/skinbiotherapeutics-plc/register-investor)
.

 

-Ends-

For more information please contact:

 

 SkinBioTherapeutics plc                                 +44 (0) 191 495 7325
 Stuart J. Ashman, CEO
 Simon Hewitson, COO

 Singer Capital Markets(Nominated Adviser & Broker)      +44 (0) 020 7496 3000
 Philip Davies
 Sam Butcher
 Patrick Weaver

 Vigo Consulting (financial press)                       +44 (0) 20 7390 0230
 Rozi Morris                                             SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic
pillar has a partnership with Croda plc and the Group's first in-house
product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of
inflammatory skin conditions, is sold directly and via Amazon, and will be
sold via an exclusive UK commercial deal with Superdrug Stores plc later in
2025.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIGDLCDDDGUC